Gilead Sciences was a hope for many when looking at the pandemic. Gilead’s Remdesivir was the first to receive Emergency Use Authorization in the United States. Gilead was quick to help other labs gain the expertise and equipment needed to manufacture Remdesivir abroad. The company, in an act of goodwill, also gave away millions of doses in 2020. Despite all of this they still came under fire when their prices were released. As we came into 2021, there were mounting reports that despite being included in the Standard of Care for many patients, Remdesivir seemed to show minimal benefit. The upside has been that there have rarely been claims of adverse events from Remdesivir. The company had a number of acquisition in 2020-2021. Most of the work done in the videos below focus on the projections of Remdesivir sales and the impact on the firm’s equity valuation
